[Skip to Content]
[Skip to Content Landing]
July 25, 1953


JAMA. 1953;152(13):1198-1201. doi:10.1001/jama.1953.03690130014003

The management of the various types of shock, each characterized by its own combination of circulatory disturbances,1 is still far from perfect. Recently, the employment of intra-arterial transfusion2 and vasopressor drugs3 for shock has begun to receive increasing attention. The present report is a clinical evaluation of arterenol, a vasopressor drug, in the treatment of shock from various causes.

RATIONALE OF VASOPRESSOR DRUG THERAPY IN SHOCK  Whole blood is the most effective substance to combat shock due to hemorrhage; however, blood (or plasma) is not always immediately available, and other methods of treatment must be employed in the interim. Furthermore, blood and blood products, on occasion, are not effective in reversing the profound hypotension of severe blood loss, and adjuvant therapy is then desirable. Under these circumstances, vasopressor drug therapy would be indicated to combat the severe peripheral vascular collapse.Severe cardiogenic shock, initiated by the inability

First Page Preview View Large
First page PDF preview
First page PDF preview